TTrialPathMatch Me to Trials
← Back to trials
RecruitingPlatinum-sensitive Relapsed Epithelial Ovarian CancerPlatinum-sensitive Relapsed Fallopian Tube CancerPlatinum-sensitive Relapsed Primary Peritoneal Cancer

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

Eligible age

18+ yrs

Accepts

Women

Locations

14 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Sponsor: AstraZeneca

You may qualify if…

  • ✓ Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
  • ✓ Provision of an archival FFPE tumour sample
  • ✓ Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
  • ✓ Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
  • ✓ Participants who received 4-6 cycles of PBC during the induction phase of their current line of treatment.
  • ✓ Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
  • ✓ Participants with non-progressive disease upon completion of PBC in their current line of treatment.
  • ✓ Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).

You may not qualify if…

  • ✕ Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.
  • ✕ Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
  • ✕ Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
  • ✕ Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
  • ✕ Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

Where it's recruiting

Alaska

Anchorage

Florida

Miami

Indiana

Indianapolis

Louisiana

Shreveport

Maryland

Columbia

Michigan

Ann Arbor · Detroit

New York

Albany · Bay Shore · Buffalo · Greenlawn …

Ohio

Cleveland · Columbus · Mayfield Heights

Oklahoma

Oklahoma City

Pennsylvania

Philadelphia · Willow Grove

Texas

Houston

Utah

Salt Lake City

Source: ClinicalTrials.gov · NCT07816666 · last updated 2026-10-16